Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy
For over fifteen years, the “who’s who” in Asset Recovery and Insolvency from around the globe have made it a point to attend this event – widely regarded as the true destination and.